| The next year promises several potential new blockbusters: from tumor-busting antibody-drug conjugates, to controversial homeopathics that aim to change the food allergy market. With help from EvaluatePharma, our list of the top 10 most-anticipated drug launches of 2020 is based on their global sales estimates for 2024—and it includes eight therapies that could break the billion-dollar barrier in less than four short years. That special report, plus the week’s top reads, are below. | |
|
Featured Story | | | Wednesday, February 5, 2020 GlaxoSmithKline made clear it intended to spin off its consumer health joint venture with Pfizer when the partners first unveiled the deal. Now, the British drugmaker has officially started a two-year journey toward that split, which may take prescription dermatology along with it. |
|
|---|
|
|  | [Webinar] Accelerating Approval for Cell and Gene Therapies Thursday, February 27 | 12pm ET / 9am PT Developers of cell and gene therapies can run into complex clinical and regulatory hurdles when bringing treatments to patients. Join experts from Cardinal Health Regulatory Sciences to explore critical factors that can help reduce the risk of failure and increase speed to market. |
Top Stories Of The Week Monday, February 3, 2020 Gilead has made progress in its effort to reposition failed Ebola drug remdesivir as a treatment for the coronavirus sweeping across China. In quick succession, it emerged that the nucleotide analogue prodrug appeared to help the first U.S. case of the virus and is set to undergo clinical testing in China, sending Gilead’s stock up by as much as 13% in premarket trading. We've assembled a list of the top 10 most-anticipated new drug launches of 2020 based on estimated global sales in 2024. Of those 10, eight could break the blockbuster barrier in four short years—putting a new batch of heavy hitters in pharma's ranks. Tuesday, February 4, 2020 Bristol-Myers Squibb has created a fibrotic and inflammatory disease biotech through its partnership with BioMotiv. The biotech, Anteros Pharmaceuticals, starts life with materials from Bristol-Myers to support development of small molecules and the potential to land a takeover by the Big Pharma. Tuesday, February 4, 2020 The value of Johnson & Johnson's brand has slipped over the last year, but the pharma and devices giant still boasts a name worth $10.9 billion, Brand Finance’s annual assessment found. Roche came in second at $7.59 billion, an increase of 9.8%, and Bayer finished third at $5.15 billion, sustaining its spot even though it dipped 17.1% in value. Monday, February 3, 2020 Alzheimer's drugs that sought to prevent amyloid plaques in the brain by blocking the enzyme gamma secretase failed several years ago, largely because of toxic side effects. Now researchers at Rensselaer Polytechnic Institute say they have found a drug that sidesteps toxicities by targeting a precursor protein. Tuesday, February 4, 2020 Novartis CEO Vas Narasimhan has been touting an “unbossed” management environment at the Swiss drugmaker. To hear chief digital officer Bertrand Bodson tell it, part of that effort includes arming employees with digital solutions. Wednesday, February 5, 2020 As GlaxoSmithKline announced it is splitting in two (with a consumer healthcare unit to become standalone), the British Big Pharma says its priority at GSK 2.0 will be R&D. Friday, January 31, 2020 Shire had big ambitions when it built a $400 million biologics plant in Ireland it said would help achieve its “ambition of becoming the world’s leading biotechnology company.” Well, Shire no longer exists. It was absorbed into Japan’s Takeda, which now intends to sell the plant with 200 employees. Monday, February 3, 2020 Abbott plans to launch a head-to-head study that puts its structural heart device up against a newer generation of blood thinners, testing its ability to lower the risk of strokes in people with atrial fibrillation. Thursday, January 30, 2020 Gilead CEO Daniel O'day said his company "will not get into a patent dispute" around remdesivir. Sanofi is planning to join other drugmakers in launching a coronavirus initiative. Bristol-Myers Squibb has restricted employee travel to and from China, as Novo Nordisk asked its employees in China to stay at home. And more. Resources Sponsored by: Medidata To conduct a successful trial, do you need to understand the global eConsent Regulatory landscape? Sponsored by: Veeva Learn how data management teams at ICON, Bioforum, and Vertex Pharmaceuticals are creating the spec and casebook in a single step, reducing study build times and effort by over 50%. Sponsored by: Quotient Sciences Tufts Center for the Study of Drug Development (CSDD) white paper sharing study results that indicate Quotient Sciences’ Translational Pharmaceutics® platform reduces development times by more than 12 months and lowers R&D costs by more than $100 million per approved new drug, compared to traditional multi-vendor development paradigms. Sponsored by: Catalent Learn how recent innovations in demand-led supply and direct-to-patient distribution are converging to create a next-generation clinical supply chain that is flexible, lean and most importantly patient-centric. Sponsored by: Altran This whitepaper highlights the challenges of implementing the right digital twin strategy while providing key use cases in the manufacturing domain for which a digital twin is extremely useful and several examples of technology trends that will shape the future. Sponsored by: Catalent Pharma Solutions In this Q&A, four Catalent Biologics experts share how scale-up, regulatory expectations, demand forecasting and process validation all play a role in the success of a biologic when embarking upon the commercial manufacturing journey. | 
